Incyte Corporation
NASDAQ · INCY·Wilmington, DE·Large-cap·Approved
Biopharmaceutical company anchored by Jakafi (ruxolitinib) in myelofibrosis and polycythemia vera, with Opzelura in atopic dermatitis and vitiligo. Incyte's pipeline spans JAK inhibitors and novel oncology targets including FGFR, PD-1, and bispecific antibodies.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Incyte Corporate Presentation | Corporate overview | January 1, 2026 | 31 |